Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883747 · ClinicalTrials.gov registry record · Early Phase 1
Clinical Trial of BMS-986504 in Recurrent GBM Patients
A Early Phase 1 study of Glioblastoma WHO Grade IV, sponsored by Nader Sanai.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT06883747 is a Early Phase 1 study of Glioblastoma WHO Grade IV that is actively recruiting participants, run by Nader Sanai. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06883747, a Early Phase 1 study of Glioblastoma WHO Grade IV, is actively recruiting participants, sponsored by Nader Sanai.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 9 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are scheduled for surgical resection. MTAP loss/deletion will be determined by next-generation sequencing (NGS). The trial will include a dose escalation design to evaluate the pharmacokinetics (PK) and safety and tolerability of BMS-986504 (MRTX1719). The trial will be composed of a Phase 0 component and an Expansion Phase 1 component. Participants with tumors demonstrating a positive PK response in the Phase 0 component of the study will be eligible to enroll into the the Phase 1 component that will include 21-day cycles of therapeutic dosing of BMS-986504.
Conditions Studied
Interventions
- DRUG BMS-986504
Study Locations (1)
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2027-09-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06883747
The ClinicalTrials.gov registry entry for NCT06883747 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nader Sanai, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma WHO Grade IV appearing as the primary indexed condition, and to 1 intervention - of which BMS-986504 is the first listed.
NCT06883747 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06883747 about?
NCT06883747 is a clinical study titled "Clinical Trial of BMS-986504 in Recurrent GBM Patients". This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 9 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are scheduled for surgical resection. MTAP loss/deletion will be det...
What is the current status of trial NCT06883747?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2025-04-28. Estimated completion is 2027-09-28.
What conditions does trial NCT06883747 study?
This clinical trial studies the following conditions: Glioblastoma WHO Grade IV.
What interventions are being tested in trial NCT06883747?
The interventions under investigation include: BMS-986504 (DRUG).
Who is sponsoring clinical trial NCT06883747?
This trial is sponsored by Nader Sanai, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883747 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma WHO Grade IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas
ACTIVE NOT RECRUITING · Early Phase 1
-
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.